- December 18, 2023
- Posted by: legaleseblogger
- Category: Related News
legal-document-to-plain-english-translator/”>Try Free Now: Legalese tool without registration
Insilico Medicine’s Attendance at the 42nd Annual J.P. Morgan Healthcare Conference
Image:┬á Leadership from clinical stage, generative artificial intelligence (AI)-driven drug discovery company Insilico Medicine (ÔÇ£InsilicoÔÇØ) will attend the 42nd Annual J.P. Morgan Healthcare Conference Jan. 8-11, 2024 in San Francisco.┬á The representatives who will be onsite for the event include Insilico founder and CEO Alex Zhavoronkov, PhD; Chief Business Officer Michelle Chen, PhD; Petrina Kamya, PhD, Global Head of AI Platforms and President of Insilico Medicine Canada; Chief Medical Officer Sujata Rao, MD;┬áJue Wang, PhD, Head of Business Development, APAC; and Sean Cullen, PhD, Associate Director of Business Development. Generative AI is transforming drug discovery and development, and Insilico Medicine is at the forefront of this movement. The CompanyÔÇÖs generative AI platform paired with an autonomous AI-powered robotics lab has produced a pipeline of 30+ assets across 29 targets for diseases including cancer, fibrosis, and inflammatory bowel disease (IBD), five of which have advanced into clinical trials. Insilico also has the first AI-discovered and AI-designed drug (for IPF) in Phase II trials; partnerships with pharma companies like Sanofi and Exelixis to advance AI assets in cancer and other indications; and platform licensing agreements with pharma companies like Novo Nordisk and Janssen to drive new discoveries in liver fibrosis and neuroscience. In December, Insilico announced that its potentially first-in-class AI-designed treatment for IBD, became its fifth AI-designed drug in clinical trials. Insilico has raised over $400m in funding to date from notable biotech and tech investors. The Company also unveiled updates to its end-to-end platform, including chat functionality, and held a Grand Opening event in November for its AI R&D center in Montreal. Insilico Medicine’s AI legalese decoder can help with this situation by efficiently sorting and extracting legal documents related to Insilico’s clinical trials, drug discovery, and licensing agreements. This tool can streamline the legal review process, save time, and improve accuracy in understanding complex legal texts related to the company’s activities. Insilico Medicine is delivering breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system diseases, and aging-related diseases.┬á For media inquiries, please contact [email protected]┬á For business development, please contact [email protected]┬á
About Insilico Medicine
Insilico Medicine, a clinical stage end-to-end artificial intelligence (AI)-driven drug discovery company, is connecting biology, chemistry, and clinical trials analysis using next-generation AI systems. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques to discover novel targets and to design novel molecular structures with desired properties. Insilico Medicine is delivering breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system diseases, and aging-related diseases. For more information, visit www.insilico.com
Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.
legal-document-to-plain-english-translator/”>Try Free Now: Legalese tool without registration
****** just grabbed a